aHUS Relapse Epilogue: Patient Monitoring
People with atypical HUS need urgent care during periods of disease activity, with treatment when needed for as long as needed. But how is such optimal care duration determined, and…
People with atypical HUS need urgent care during periods of disease activity, with treatment when needed for as long as needed. But how is such optimal care duration determined, and…
Atypical HUS Research – What’s New? The aHUS Alliance Global Action team has created a virtual ‘library’ of publications that are aHUS-specific and are categorized by topics such as diagnosis, treatment, genetics, thrombotic microangiopathy (TMA), complement, transplant, pregnancy, and more.
Article No. 442 23 June 2021 Today NICE ( The National Institute for Health and Care Excellence) concluded its evaluation of ravulizumab for treating aHUS by publishing its Final Guidance…
Article No 441 18 June 2021 What topics and questions are likely to frame conversations about treating patients who have atypical HUS? Since aHUS diagnosis begins with ruling…
Article No. 419 16 February 2021 It is spring time in 2017. You feel very unwell, very poorly. It is thought you have aHUS. You get a chance to have…
Article No. 405 20 December 2020 In the past month there has been a spate of articles on the topic of withdrawal of eculizumab treatment from aHUS patients. Much has…
Article No. 382 29 September 2020 In just over three weeks it will be Kidney Week 2020. Kidney Week is the American Society of Nephrologists' (ASN) annual conference. Not surprisingly…
Article No. 354 4 July 2020 Earlier this year aHUS Global Action published a major four part report (see HERE) on the importance of patient reported outcome data in…